Innovative Pharmaceutical Serv is categorized under Services (Unclassified) in Kansas City, MO and active since 2010.
Innovative Pharmaceutical Serv was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Services (Unclassified) business, which does work in the B2B market, and is classified as a Services (Unclassified), under code number 541990 by the NAICS.
If you are seeking more information, feel free to contact Charles T Fink at the company’s single location by writing to 7506 Raytown Road, Kansas City, Missouri MO 64138 or by phoning (816) 356-0300. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Innovative Pharmaceutical Serv |
| Contact Person: | Charles T Fink |
| Address: | 7506 Raytown Road, Kansas City, Missouri 64138 |
| Phone Number: | (816) 356-0300 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Services (Unclassified) |
| SIC Code: | 8999 |
| NAICS Code: | 541990 |
| Share This Business: |
Innovative Pharmaceutical Serv was started in 2010 to provide professional Services (Unclassified) under the SIC code 8999 and NAICS code 541990. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Charles T Fink for inquiries that concern Innovative Pharmaceutical Serv by calling the company number (816) 356-0300, as your correspondence is most welcome. Additionally, the physical location of the single location of Innovative Pharmaceutical Serv can be found at the coordinates 38.985925,-94.46463 as well as the street address 7506 Raytown Road in Kansas City, Missouri 64138.
For its online presence, you may visit Innovative Pharmaceutical Serv’s website at and engage with its social media outlets through on Twitter and on Facebook.